Cipla Q1 profit rises 10% to ₹451 crore, tops estimates
Cipla’s net profit rose 10.4% from a year earlier to ₹451 crore in the first quarter ended 30 June
Bengaluru: Cipla Ltd, India’s third-largest drugmaker by market capitalisation, posted a more than 10% rise in its first-quarter profit on Wednesday, well above analysts’ expectations.
Net profit rose 10.4% from a year earlier to ₹451 crore ($65.67 million) in the first quarter ended 30 June, the drugmaker said on Wednesday.
This compared with an average analyst expectation of ₹391crore, according to Thomson Reuters I/B/E/S.
Net sales rose 12% to ₹3,846 crore, the company said in a statement.
Revenue from India, which accounted for more than a third of the total revenue, jumped 22% to ₹1,544 crore.
North America business posted 4% growth, Cipla said.
The company has appointed R. Ananthanarayanan as global chief operating officer to oversee its businesses in North America, Europe and emerging markets.
Shares in Cipla closed 0.5% higher in a Mumbai market that rose 0.5%.
Editor's Picks »
- Cabinet approves ₹6,000 crore capital infusion in Exim Bank
- Apax Funds invests $200 million in Fractal Analytics
- Govt panel likely to meet on Jan 24 to appoint new CBI Director: Sources
- Cabinet panel approves trebling of Numaligarh refinery capacity at Rs 22,594 crore
- Trai ticks off Tata Sky for lack of customer support on new regulations
- Why Tata Motors’ Project Charge at JLR is failing to recharge its shares
- Outlook on global profit growth worst since 2008 financial crisis
- Q3 results: ICICI Securities loses its retail broking crown
- High drug approvals to keep up pricing pressure for pharma firms
- Roads sector: Toll collections set to surge, but risks loom for developers